MCID: CCN001
MIFTS: 48

Cocaine Dependence

Categories: Mental diseases

Aliases & Classifications for Cocaine Dependence

MalaCards integrated aliases for Cocaine Dependence:

Name: Cocaine Dependence 12 74 54 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9975
ICD9CM 34 304.2 304.20
MeSH 43 D019970
NCIt 49 C34492
SNOMED-CT 67 31956009
ICD10 32 F14.2
UMLS 71 C0600427

Summaries for Cocaine Dependence

Disease Ontology : 12 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary : Cocaine Dependence is related to avoidant personality disorder and smoking as a quantitative trait locus 3. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Carbamazepine and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Cocaine dependence is a psychological desire to use cocaine regularly. Cocaine overdose may result in... more...

Related Diseases for Cocaine Dependence

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.2 SLC6A4 SLC6A3 DRD3 DRD2
2 smoking as a quantitative trait locus 3 30.9 CHRNA5 CHRNA3
3 cannabis dependence 30.8 GABRA2 COMT CNR1
4 personality disorder 30.6 SLC6A4 SLC6A3 PRL HTR2A DRD3 DRD2
5 cocaine abuse 30.6 SLC6A4 SLC6A3 PRL OPRK1 DRD3 DRD2
6 alexithymia 30.5 SLC6A4 DRD2 COMT
7 antisocial personality disorder 30.4 SLC6A4 SLC6A3 PRL HTR2A GABRA2 DRD2
8 traumatic brain injury 30.4 DRD2 COMT
9 polysubstance abuse 30.2 DRD3 DRD2 COMT CNR1
10 cannabis abuse 30.1 OPRM1 GABRA2 DRD2 COMT CNR1
11 social phobia 30.1 SLC6A4 PRL DRD2 COMT
12 borderline personality disorder 30.1 SLC6A4 SLC6A3 PRL HTR2A DRD2 COMT
13 mental depression 30.1 SLC6A4 SLC6A3 POMC HTR2A DRD2 DRD1
14 movement disease 30.0 SLC6A3 DRD3 DRD2 DRD1
15 psychotic disorder 29.9 SLC6A4 SLC6A3 PRL PDYN OPRM1 HTR2A
16 opiate dependence 29.8 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
17 bipolar i disorder 29.8 SLC6A4 HTR2A DRD3 DRD2 DRD1 COMT
18 hyperprolactinemia 29.7 PRL POMC HTR2A DRD2 DBH
19 attention deficit-hyperactivity disorder 29.7 SLC6A4 SLC6A3 PRL OPRM1 HTR2A DRD3
20 heroin dependence 29.7 SLC6A4 SLC6A3 PDYN OPRM1 OPRD1 DRD3
21 alcohol use disorder 29.6 SLC6A4 SLC6A3 OPRM1 HTR2A GABRA2 DRD3
22 pathological gambling 29.6 SLC6A4 SLC6A3 HTR2A DRD3 DRD2 DRD1
23 sleep disorder 29.6 SLC6A4 SLC6A3 PRL POMC HTR2A DRD2
24 mood disorder 29.6 SLC6A4 SLC6A3 POMC HTR2A DRD3 DRD2
25 post-traumatic stress disorder 29.6 SLC6A4 POMC HTR2A DRD2 DBH COMT
26 conduct disorder 29.5 SLC6A4 SLC6A3 POMC GABRA2 DRD2 DBH
27 substance-induced psychosis 29.3 SLC6A3 HTR2A DRD3 DRD2 DRD1 COMT
28 withdrawal disorder 29.3 POMC PDYN OPRM1 OPRK1 OPRD1 DRD2
29 opioid abuse 29.3 PDYN OPRM1 OPRK1 OPRD1 DRD3 DRD2
30 narcolepsy 29.2 SLC6A4 SLC6A3 PDYN HTR2A DRD2 DRD1
31 schizoaffective disorder 29.2 SLC6A4 PRL HTR2A DRD3 DRD2 COMT
32 eating disorder 29.0 SLC6A4 SLC6A3 POMC OPRM1 HTR2A DRD3
33 drug dependence 28.9 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
34 major depressive disorder 28.9 SLC6A4 SLC6A3 PRL POMC OPRM1 HTR2A
35 bipolar disorder 28.9 SLC6A4 SLC6A3 PRL PDYN HTR2A GABRA2
36 obsessive-compulsive disorder 28.7 SLC6A4 SLC6A3 PRL POMC PDYN HTR2A
37 substance abuse 28.6 SLC6A4 SLC6A3 PRL PDYN OPRM1 OPRK1
38 dystonia 28.4 SLC6A3 PRL PDYN HTR2A DRD3 DRD2
39 tobacco addiction 28.1 SLC6A4 SLC6A3 PDYN OPRM1 HTR2A GABRA2
40 substance dependence 27.7 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
41 anxiety 27.7 SLC6A4 SLC6A3 PRL POMC PDYN OPRM1
42 schizophrenia 27.4 SLC6A4 SLC6A3 PRL POMC PDYN OPRM1
43 alcohol dependence 27.4 SLC6A4 SLC6A3 PRL POMC PDYN OPRM1
44 cocaine intoxication 11.6
45 galactorrhea 10.6 PRL DRD2
46 adenohypophysitis 10.5 PRL POMC
47 acth-dependent cushing syndrome 10.5 PRL POMC
48 tuberculum sellae meningioma 10.5 PRL POMC
49 sella turcica neoplasm 10.5 PRL POMC
50 kleptomania 10.5 SLC6A4 DRD2

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence

Symptoms & Phenotypes for Cocaine Dependence

MGI Mouse Phenotypes related to Cocaine Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 CHRNA3 CHRNA5 CHRNB3 CNR1 COMT DBH
2 homeostasis/metabolism MP:0005376 10.16 CHRNA3 CNR1 COMT DBH DRD1 DRD2
3 digestive/alimentary MP:0005381 10.07 CHRNA3 CNR1 DRD1 DRD2 DRD3 HTR2A
4 adipose tissue MP:0005375 10.03 CNR1 DBH DRD1 DRD2 DRD3 OPRM1
5 endocrine/exocrine gland MP:0005379 10.02 COMT DBH DRD2 HTR2A OPRK1 OPRM1
6 integument MP:0010771 10 CHRNA5 CNR1 DBH DRD1 DRD2 GABRA2
7 nervous system MP:0003631 9.89 CHRNA3 CHRNA5 CNR1 COMT DBH DRD1
8 no phenotypic analysis MP:0003012 9.23 CHRNA3 CNR1 DRD2 GABRA2 OPRD1 OPRM1

Drugs & Therapeutics for Cocaine Dependence

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
2
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
6
Choline Approved, Nutraceutical Phase 4 62-49-7 305
7 Cytochrome P-450 CYP3A Inducers Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Sodium Channel Blockers Phase 4
10 Diuretics, Potassium Sparing Phase 4
11 Antipsychotic Agents Phase 4
12 Serotonin Antagonists Phase 4
13 Serotonin Agents Phase 4
14 Dopamine Antagonists Phase 4
15 Gastrointestinal Agents Phase 4
16 Calcium, Dietary Phase 4
17 calcium channel blockers Phase 4
18 Antimetabolites Phase 4
19 Quetiapine Fumarate Phase 4 111974-72-2
20 Hypolipidemic Agents Phase 4
21 Lecithin Phase 4
22 Cytidine Diphosphate Choline Phase 4
23 Lipid Regulating Agents Phase 4
24
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
25
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
26
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
27
Biperiden Approved, Investigational Phase 2, Phase 3 514-65-8 2381
28
Caffeine Approved Phase 2, Phase 3 58-08-2 2519
29
Topiramate Approved Phase 2, Phase 3 97240-79-4 5284627
30
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 52485-79-7 40400 644073
31
Levodopa Approved Phase 2, Phase 3 59-92-7 6047
32
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359
33
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
34
Mirtazapine Approved Phase 2, Phase 3 85650-52-8, 61337-67-5 4205
35
Nicotine Approved Phase 3 54-11-5 942 89594
36
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
37
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
38
Entacapone Approved, Investigational Phase 2, Phase 3 130929-57-6 5281081
39
Bupropion Approved Phase 2, Phase 3 34911-55-2, 34841-39-9 444
40
Methadone Approved Phase 2, Phase 3 76-99-3 4095
41
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
42 Serotonin Uptake Inhibitors Phase 2, Phase 3
43 Muscarinic Antagonists Phase 2, Phase 3
44 Antiparkinson Agents Phase 2, Phase 3
45 Serotonin Receptor Agonists Phase 2, Phase 3
46 Cholinergic Antagonists Phase 2, Phase 3
47 Parasympatholytics Phase 2, Phase 3
48 Phosphodiesterase Inhibitors Phase 2, Phase 3
49 Biperiden lactate Phase 2, Phase 3
50 Hormone Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 310)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
3 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
4 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
5 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
6 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4 Modafinil;Placebo
7 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
8 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
9 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
10 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Disorder Recruiting NCT02927236 Phase 4
11 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
12 Medication Development for Cocaine Dependence Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
13 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
14 Dose Response Trial of Pergolide for Cocaine Dependence Completed NCT00000248 Phase 3 Pergolide
15 Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence Completed NCT00032929 Phase 3 Selegiline
16 Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
17 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
18 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
19 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
20 Effect of Nefazodone on Relapse in Females With Cocaine Abuse Completed NCT00000293 Phase 3 Nefazodone
21 Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
22 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
23 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
24 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
25 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00218660 Phase 3 Naltrexone;Placebo
26 Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
27 A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
28 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes Completed NCT01077024 Phase 3
29 Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
30 Project 1: Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
31 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
32 A Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders Completed NCT01979133 Phase 3 Icariin
33 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
34 Bupropion-Enhanced CM for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
35 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
36 Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence. Unknown status NCT01397266 Phase 2
37 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
38 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
39 Effect of Repetitive Transcranial Magnetic Stimulation on Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
40 Carbamazepine Treatment for Cocaine Dependence Completed NCT00000191 Phase 2 Carbamazepine
41 Selegiline in Treatment of Cocaine Dependence Completed NCT00000188 Phase 2 Selegiline
42 Ritanserin in Treatment of Cocaine Dependence Completed NCT00000187 Phase 2 Ritanserin
43 Modafinil for the Treatment of Cocaine Dependence Completed NCT00100100 Phase 2 Modafinil
44 Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence Completed NCT00082485 Phase 2 Baclofen
45 A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence Completed NCT00385801 Phase 2 Risperidone;Placebo
46 Serotonin, Impulsivity, and Cocaine Dependence Treatment Completed NCT00297505 Phase 2 citalopram
47 Risperidone for the Treatment of Cocaine Dependence Completed NCT00000342 Phase 2 Risperidone
48 Double-Blind, Placebo-Controlled Trial of Ondansetron for the Treatment of Cocaine Dependence Completed NCT00033085 Phase 2 Ondansetron
49 Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence Completed NCT00033033 Phase 2 Reserpine
50 Naltrexone in Treatment of Cocaine Dependence Completed NCT00015080 Phase 2 Naltrexone

Search NIH Clinical Center for Cocaine Dependence

Genetic Tests for Cocaine Dependence

Anatomical Context for Cocaine Dependence

MalaCards organs/tissues related to Cocaine Dependence:

40
Brain, Heart, Pituitary, Testes, Cortex, Prefrontal Cortex, Amygdala

Publications for Cocaine Dependence

Articles related to Cocaine Dependence:

(show top 50) (show all 1655)
# Title Authors PMID Year
1
Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. 54 61
20170711 2010
2
Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence. 54 61
19503018 2009
3
mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. 54 61
19720750 2009
4
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. 54 61
18923396 2009
5
Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. 54 61
19349312 2009
6
Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. 54 61
18321529 2008
7
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? 54 61
15988468 2005
8
Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. 54 61
15091312 2004
9
Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. 54 61
15545018 2004
10
Dopamine transporter as target for drug development of cocaine dependence medications. 54 61
14612141 2003
11
No association between polymorphisms in the serotonin transporter gene and susceptibility to cocaine dependence among African-American individuals. 54 61
12218660 2002
12
PET studies of brain monoamine transporters. 54 61
10974156 2000
13
Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. 54 61
11092766 2000
14
Family-based study of DRD2 alleles in alcohol and drug dependence. 54 61
11054774 2000
15
Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence. 54 61
10523822 1999
16
No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. 54 61
10023512 1999
17
Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence? 54 61
9154209 1997
18
No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. 54 61
12893467 1996
19
Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. 54 61
7865100 1994
20
Allelic association of the D2 dopamine receptor gene with cocaine dependence. 54 61
8261891 1993
21
Cocaine'omics: Genome-wide and transcriptome-wide analyses provide biological insight into cocaine use and dependence. 61
30734435 2020
22
Interpersonal Risk Factors for Suicide in Cocaine Dependence: Association with Self-Esteem, Personality Traits, and Childhood Abuse. 61
32030810 2020
23
White matter integrity alternations associated with cocaine dependence and long-term abstinence: Preliminary findings. 61
31783090 2020
24
Post-GWAS analysis of six substance use traits improves the identification and functional interpretation of genetic risk loci. 61
31785998 2020
25
Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist. 61
31557508 2020
26
Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. 61
31753736 2020
27
Cocaine dependence: "Side effects" and syndrome formation within 1-12 months after first cocaine use. 61
31753734 2020
28
Retrospective Association Analysis of Longitudinal Binary Traits Identifies Important Loci and Pathways in Cocaine Use. 61
31591132 2019
29
Lipidomic changes in the rat hippocampus following cocaine conditioning, extinction, and reinstatement of drug-seeking. 61
31701674 2019
30
Identifying cognitive deficits in cocaine dependence using standard tests and machine learning. 61
31352033 2019
31
Hypothalamic Responses to Cocaine and Food Cues in Individuals with Cocaine Dependence. 61
31420667 2019
32
Escalation of drug use in persons dually diagnosed with opioid and cocaine dependence: Gender comparison and dimensional predictors. 61
31698322 2019
33
Potent and selective NOP receptor activation reduces cocaine self-administration in rats by lowering hedonic set point. 61
31709687 2019
34
Genome-wide DNA methylation profile in the peripheral blood of cocaine and crack dependents. 61
31116258 2019
35
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. 61
31230464 2019
36
Neural correlates of oxytocin and cue reactivity in cocaine-dependent men and women with and without childhood trauma. 61
31701163 2019
37
Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial. 61
31908066 2019
38
Psychiatric Comorbidity in Treatment-Seeking Alcohol Dependence Patients With and Without ADHD. 61
26269096 2019
39
Web-based self-help with and without chat counseling to reduce cocaine use in cocaine misusers: Results of a three-arm randomized controlled trial. 61
31193584 2019
40
Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting. 61
31368770 2019
41
Are trait impulsivity and exposure to cannabis or alcohol associated with the age of trajectory of cocaine use? A gender-specific dimensional analysis in humans with cocaine dependence diagnosis. 61
31424236 2019
42
Motivational factors modulate left frontoparietal network during cognitive control in cocaine addiction. 61
31436010 2019
43
Genome-wide association meta-analysis of cocaine dependence: Shared genetics with comorbid conditions. 61
31212010 2019
44
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. 61
31087723 2019
45
Multimodal neurocognitive markers of interoceptive tuning in smoked cocaine. 61
30867552 2019
46
Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. 61
31165574 2019
47
Classification of cocaine-dependent participants with dynamic functional connectivity from functional magnetic resonance imaging data. 61
30957276 2019
48
Adulterants in crack cocaine in Brazil. 61
31314858 2019
49
Psychiatric factors affecting recovery after a long term treatment program for substance use disorder. 61
31128488 2019
50
Determination of cocaine adulterants in human urine by dispersive liquid-liquid microextraction and high-performance liquid chromatography. 61
31123783 2019

Variations for Cocaine Dependence

Expression for Cocaine Dependence

Search GEO for disease gene expression data for Cocaine Dependence.

Pathways for Cocaine Dependence

Pathways related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 PRL POMC PDYN OPRM1 OPRK1 OPRD1
2
Show member pathways
12.72 SLC6A4 SLC6A3 GABRA2 COMT CHRNB3 CHRNA5
3
Show member pathways
12.51 SLC6A3 DRD3 DRD2 DRD1 COMT CHRNA3
4 12.44 POMC OPRM1 DBH COMT CNR1
6
Show member pathways
11.85 SLC6A3 PDYN DRD2 DRD1
7
Show member pathways
11.8 HTR2A DRD3 DRD2 DRD1
8 11.74 HTR2A DRD3 CNR1
9
Show member pathways
11.71 DRD3 DRD2 CHRNA5 CHRNA3
10 11.67 HTR2A DRD2 DRD1
11
Show member pathways
11.62 CHRNB3 CHRNA5 CHRNA3
12
Show member pathways
11.3 SLC6A4 SLC6A3 DBH
13
Show member pathways
11.02 SLC6A4 SLC6A3 COMT
14 10.78 DRD3 DRD2 DRD1
15 10.63 PRL POMC DRD2
16
Show member pathways
10.53 SLC6A4 SLC6A3 DRD3 DRD2 DRD1 DBH

GO Terms for Cocaine Dependence

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.49 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 HTR2A
2 integral component of membrane GO:0016021 10.38 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 HTR2A
3 plasma membrane GO:0005886 10.25 SLC6A4 SLC6A3 PDYN OPRM1 OPRK1 OPRD1
4 synapse GO:0045202 10.08 SLC6A4 OPRK1 GABRA2 DBH CHRNB3 CHRNA5
5 neuronal cell body GO:0043025 9.99 SLC6A3 PDYN HTR2A GABRA2 CHRNA3
6 neuron projection GO:0043005 9.99 SLC6A4 SLC6A3 GABRA2 CHRNB3 CHRNA5 CHRNA3
7 axon GO:0030424 9.98 SLC6A3 OPRM1 HTR2A GABRA2 DRD2 COMT
8 glutamatergic synapse GO:0098978 9.97 HTR2A DRD3 DRD2 DRD1 CNR1
9 dendrite GO:0030425 9.97 PDYN OPRM1 HTR2A GABRA2 DRD2 DRD1
10 postsynaptic membrane GO:0045211 9.93 OPRD1 GABRA2 COMT CHRNB3 CHRNA5 CHRNA3
11 membrane raft GO:0045121 9.92 SLC6A4 SLC6A3 OPRM1 OPRD1 CNR1
12 GABA-ergic synapse GO:0098982 9.8 GABRA2 DRD3 DRD2 DRD1 CNR1
13 integral component of plasma membrane GO:0005887 9.8 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 HTR2A
14 axon terminus GO:0043679 9.75 PDYN OPRD1 DRD2
15 integral component of postsynaptic membrane GO:0099055 9.73 SLC6A4 SLC6A3 OPRM1 HTR2A DRD2 DRD1
16 dendrite membrane GO:0032590 9.72 OPRM1 OPRD1 GABRA2
17 acetylcholine-gated channel complex GO:0005892 9.67 CHRNB3 CHRNA5 CHRNA3
18 spine apparatus GO:0097444 9.56 OPRM1 OPRD1
19 dopaminergic synapse GO:0098691 9.55 SLC6A3 DRD3 DRD2 CHRNB3 CHRNA5
20 integral component of presynaptic membrane GO:0099056 9.23 SLC6A4 SLC6A3 OPRM1 OPRD1 HTR2A DRD2

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.24 POMC PDYN OPRM1 OPRK1 OPRD1 HTR2A
2 signal transduction GO:0007165 10.1 PRL POMC OPRM1 OPRK1 OPRD1 HTR2A
3 response to drug GO:0042493 10.07 SLC6A4 SLC6A3 HTR2A DRD3 DRD2 DRD1
4 ion transmembrane transport GO:0034220 10.05 GABRA2 CHRNB3 CHRNA5 CHRNA3
5 response to ethanol GO:0045471 9.99 SLC6A3 OPRM1 DRD3 DRD2 CNR1
6 regulation of membrane potential GO:0042391 9.98 GABRA2 CHRNB3 CHRNA5 CHRNA3
7 neuropeptide signaling pathway GO:0007218 9.98 POMC PDYN OPRM1 OPRK1 OPRD1
8 memory GO:0007613 9.95 SLC6A4 HTR2A DRD1 DBH CNR1
9 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.94 OPRM1 OPRK1 OPRD1 HTR2A
10 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.93 DRD3 DRD2 DRD1 CNR1
11 sensory perception of pain GO:0019233 9.93 OPRM1 OPRK1 HTR2A CNR1
12 response to toxic substance GO:0009636 9.92 SLC6A4 DRD3 DRD2
13 nervous system process GO:0050877 9.92 GABRA2 CHRNB3 CHRNA5 CHRNA3
14 chemical synaptic transmission GO:0007268 9.92 PDYN OPRK1 HTR2A GABRA2 DBH CHRNB3
15 visual learning GO:0008542 9.91 DRD3 DRD2 DRD1 DBH
16 excitatory postsynaptic potential GO:0060079 9.91 OPRM1 DRD2 CHRNB3 CHRNA5 CHRNA3
17 learning GO:0007612 9.9 DRD3 DRD1 COMT
18 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.89 OPRM1 OPRK1 OPRD1
19 regulation of postsynaptic membrane potential GO:0060078 9.89 GABRA2 CHRNB3 CHRNA5
20 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.89 OPRM1 OPRD1 HTR2A DRD1 CNR1
21 neurotransmitter transport GO:0006836 9.88 SLC6A4 SLC6A3 GABRA2
22 response to amphetamine GO:0001975 9.88 DRD3 DRD2 DRD1 DBH
23 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.87 DRD3 DRD2 DRD1
24 neuromuscular synaptic transmission GO:0007274 9.87 CHRNB3 CHRNA5 CHRNA3
25 response to morphine GO:0043278 9.87 OPRM1 DRD3 DRD2 CNR1
26 regulation of dopamine secretion GO:0014059 9.86 HTR2A DRD3 DRD2
27 regulation of sensory perception of pain GO:0051930 9.86 OPRM1 OPRD1 COMT
28 associative learning GO:0008306 9.85 DRD2 DRD1 DBH
29 negative regulation of blood pressure GO:0045776 9.85 DRD3 DRD2 CNR1
30 synaptic transmission, cholinergic GO:0007271 9.85 CHRNB3 CHRNA5 CHRNA3
31 regulation of synaptic vesicle exocytosis GO:2000300 9.85 HTR2A DRD2 DRD1 CHRNB3 CHRNA5
32 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.84 DRD3 DRD2 DRD1
33 temperature homeostasis GO:0001659 9.83 HTR2A DRD2 DRD1
34 dopamine receptor signaling pathway GO:0007212 9.83 DRD3 DRD2 DRD1
35 synaptic transmission, dopaminergic GO:0001963 9.83 DRD3 DRD2 DRD1
36 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.82 HTR2A DRD3 DRD2
37 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.82 DRD3 DRD2 DRD1
38 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.79 OPRM1 DRD3 DRD1
39 opioid receptor signaling pathway GO:0038003 9.79 OPRM1 OPRK1 OPRD1
40 behavioral response to cocaine GO:0048148 9.78 HTR2A DRD3 DRD2 DRD1
41 dopamine catabolic process GO:0042420 9.77 SLC6A3 DBH COMT
42 negative regulation of voltage-gated calcium channel activity GO:1901386 9.75 DRD3 DRD2
43 neurotransmitter biosynthetic process GO:0042136 9.74 SLC6A4 SLC6A3
44 positive regulation of renal sodium excretion GO:0035815 9.74 DRD3 DRD2
45 regulation of synaptic transmission, GABAergic GO:0032228 9.74 DRD2 CNR1
46 grooming behavior GO:0007625 9.74 DRD2 DRD1
47 G protein-coupled receptor internalization GO:0002031 9.74 DRD3 DRD2
48 striatum development GO:0021756 9.74 DRD2 DRD1
49 maternal behavior GO:0042711 9.74 DRD1 DBH
50 regulation of potassium ion transport GO:0043266 9.73 DRD3 DRD2

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.97 OPRM1 OPRK1 OPRD1 HTR2A DRD3 DRD2
2 ion channel activity GO:0005216 9.81 GABRA2 CHRNB3 CHRNA5 CHRNA3
3 peptide binding GO:0042277 9.7 OPRM1 OPRK1 OPRD1
4 neuropeptide binding GO:0042923 9.67 OPRM1 OPRK1 OPRD1
5 adrenergic receptor activity GO:0004935 9.65 DRD3 DRD2 DRD1
6 acetylcholine binding GO:0042166 9.63 CHRNB3 CHRNA5 CHRNA3
7 extracellular ligand-gated ion channel activity GO:0005230 9.62 GABRA2 CHRNB3 CHRNA5 CHRNA3
8 acetylcholine-gated cation-selective channel activity GO:0022848 9.61 CHRNB3 CHRNA5 CHRNA3
9 acetylcholine receptor activity GO:0015464 9.58 CHRNB3 CHRNA5 CHRNA3
10 serotonin binding GO:0051378 9.56 SLC6A4 HTR2A
11 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.55 DRD3 DRD2
12 monoamine transmembrane transporter activity GO:0008504 9.54 SLC6A4 SLC6A3
13 opioid receptor activity GO:0004985 9.43 OPRM1 OPRK1 OPRD1
14 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD3 DRD2 DRD1
15 dopamine binding GO:0035240 9.26 SLC6A3 DRD3 DRD2 DRD1
16 drug binding GO:0008144 9.1 SLC6A3 HTR2A DRD3 DRD2 CNR1 CHRNB3

Sources for Cocaine Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....